Nivolumab plus ipilimumab combined with chemotherapy as first-line treatment for HER2-negative unresectable advanced or recurrent gastric/gastroesophageal junction cancer: A randomized phase 3 trial (ATTRACTION-6).
Year: 2026
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Do-Youn Oh, Yoon-Koo Kang, Kohei Shitara, Li-Tzong Chen, Narikazu Boku, Min-Hee Ryu, Sun Young Rha, Jong Gwang Kim, Jin Young Kim, Sang Cheul Oh, Keun-Wook Lee, Jeeyun Lee, Akihito Kawazoe, Hirokazu Shoji, Kensei Yamaguchi, Sung Yong Oh, Li-Yuan Bai, Ming-Huang Chen, Jen-Shi Chen, Kun-Huei Yeh, ATTRACTION-6 Study Group
Institutions: Seoul National University, Asan Medical Center, National Cancer Center Hospital East, Kaohsiung Medical University Chung-Ho Memorial Hospital, The University of Tokyo, University of Ulsan, Yonsei University, Yonsei Cancer Hospital, Kyungpook National University, Keimyung University Dongsan Medical Center, Keimyung University Dongsan Hospital, Dong-A University Hospital, Korea University Guro Hospital, Seoul National University Bundang Hospital, Samsung Medical Center, Sungkyunkwan University, National Cancer Center Hospital, The Cancer Institute Hospital, Japanese Foundation For Cancer Research, China Medical University Hospital, Taipei Veterans General Hospital, Chang Gung University, Chang Gung Memorial Hospital, Linkou Chang Gung Memorial Hospital, National Taiwan University Hospital
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
Funder: Ono Pharmaceutical
OpenAlex ID: W7162564767